Wouter Piepers News Today : Breaking News, Live Updates & To

Oxurion NV to Focus Resources on Clinical Assets THR-687 and THR-149

Published: June 25, 2021

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Oxurion NV: OXURION Confirms Institutional Review Board Approval and Submission of the Investigational New Drug Application to the FDA to Start Phase 2 Study Evaluating THR-687 for Diabetic Macular Edema (DME)

Published: June 10, 2021

THR-687 is a potent pan-RGD integrin antagonistholding potential as next generation first line therapy for DME Leuven, BE, Boston, MA, US - June 10, 2021 - 07.00 AM CET - Oxurion

Source: finanznachrichten.de

Investegate |Oxurion NV Announcements | Oxurion NV: OXURION NV Presenting Scientific Data at ARVO 2021 Annual Meeting

Published: April 30, 2021

Investegate announcements from Oxurion NV, OXURION NV Presenting Scientific Data at ARVO 2021 Annual Meeting

Source: investegate.co.uk

OXURION NV Presenting Scientific Data at ARVO 2021 Annual Meeting

Published: April 30, 2021

Press release content from Globe Newswire. The AP news staff was not involved in its creation. OXURION NV Presenting Scientific Data at ARVO 2021 Annual Meeting Oxurion NVApril 30, 2021 GMT Leuven, BE, Boston, MA, US – April 30st, 2021 – 7.30 AM CET – Oxurion NV (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies with a clinical stage portfolio in retinal vascular disorders. Oxurion NV is announcing the presentation of novel scientific data at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 20...

Source: apnews.com

Investegate |Oxurion NV Announcements | Oxurion NV: OXURION NV to Present at Wet AMD and DME Drug Development Summit

Published: April 13, 2021

Investegate announcements from Oxurion NV, OXURION NV to Present at Wet AMD and DME Drug Development Summit